Maxim analyst Jason McCarthy upgraded Vistagen to Buy from Hold with a $30 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on VTGN:
- Vistagen skyrockets after social anxiety disorder trial hits primary endpoint
- Vistagen (NASDAQ:VTGN) Skyrockets over 600% on Positive Phase 3 Data for Social Anxiety Disorder
- VistaGen Therapeutics trading resumes
- VistaGen Therapeutics trading halted, news pending
- Vistagen announces new itruvone data